Cactusの空売り状況は、投資家がCactusの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Cactus (NYSE:WHD) 株価情報, 空売り情報

Cactus

Cactus Inc is engaged in the designing, manufacturing, and sale of wellheads and pressure control equipment. Its principal products include Cactus SafeDrill wellhead systems, conventional wellheads, and production valves among others. The company also provides mission-critical field services, including service crews to assist with the installation, maintenance, and safe handling of the wellhead and pressure control equipment, as well as repair services for equipment that it sells or rents. It sells or rents its products principally for onshore unconventional oil and gas wells that are utilized during the drilling, completion (including fracturing), and production. The company has two operating segments; Pressure Control, which generates key revenue and Spoolable Technologies.

Cactus Inc

<p>Materion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTRN#NYSE">MTRN</a>) is preparing to release its quarterly earnings on Thursday, 2025-05-01. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Materion to report an <strong>earnings per share</strong> (EPS) of $1.04.</p>
<p>Materion bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Earnings Track Record</h3>
<p>In the previous earnings release, the company missed EPS by $0.01, leading to a 3.39% drop in the share price the following trading session.</p>
<p>Here's a look at Materion's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.45</td>
<td>1.41</td>
<td>1.41</td>
<td>0.96</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.44</td>
<td>1.41</td>
<td>1.42</td>
<td>0.96</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-3.0%</td>
<td>-3.0%</td>
<td>11.0%</td>
<td>-5.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746039763_0.png" alt="eps graph" /></p>
<h3>Market Performance of Materion's Stock</h3>
<p>Shares of Materion were trading at $83.16 as of April 29. Over the last 52-week period, shares are down 24.96%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/MTRN/earnings"><strong>To track all earnings releases for Materion visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

MTRN

Earnings Preview: Materion

<p>MGP Ingredients (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGPI#NASDAQ">MGPI</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-05-01. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that MGP Ingredients will report an <strong>earnings per share</strong> (EPS) of $0.37.</p>
<p>Investors in MGP Ingredients are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Performance in Previous Earnings</h3>
<p>During the last quarter, the company reported an EPS beat by $0.07, leading to a 3.23% increase in the share price on the subsequent day.</p>
<p>Here's a look at MGP Ingredients's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.50</td>
<td>1.25</td>
<td>1.56</td>
<td>0.98</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.57</td>
<td>1.29</td>
<td>1.71</td>
<td>1.07</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>3.0%</td>
<td>-5.0%</td>
<td>-1.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746039756_0.png" alt="eps graph" /></p>
<h3>Performance of MGP Ingredients Shares</h3>
<p>Shares of MGP Ingredients were trading at $29.55 as of April 29. Over the last 52-week period, shares are down 64.16%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<h3>Analyst Opinions on MGP Ingredients</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding MGP Ingredients.</p>
<p>Analysts have given MGP Ingredients a total of 3 ratings, with the consensus rating being Buy. The average one-year price target is $39.0, indicating a potential 31.98% upside.</p>
<h3>Peer Ratings Comparison</h3>
<p>In this comparison, we explore the analyst ratings and average 1-year price targets of  and MGP Ingredients, three prominent industry players, offering insights into their relative performance expectations and market positioning.</p>
<h3>Peer Metrics Summary</h3>
<p>The peer analysis summary offers a detailed examination of key metrics for  and MGP Ingredients, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>MGP Ingredients</td>
<td>Buy</td>
<td>-15.87%</td>
<td>$74.47M</td>
<td>-4.75%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>MGP Ingredients ranks at the bottom for Revenue Growth among its peers. It also ranks at the bottom for Gross Profit. Additionally, it is at the bottom for Return on Equity. Overall, MGP Ingredients is positioned at the bottom compared to its peers across all key metrics.</p>
<h3>Unveiling the Story Behind MGP Ingredients</h3>
<p>MGP Ingredients Inc is a producer and supplier of premium distilled spirits and specialty wheat protein and starch food ingredients. MGP also produces high-quality industrial alcohol for use in both food and non-food applications. It operates in three segments: Distillery Solutions, Branded Spirits Segment, and Ingredient Solutions. Distillery Solutions provides distillery co-products, such as distillers feed, fuel grade alcohol, and corn oil: and warehouse services, including barrel put away, storage, and retrieval services. It derives its revenue from the Distillery Solutions segment.</p>
<h3>Key Indicators: MGP Ingredients's Financial Health</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> MGP Ingredients's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately <strong>-15.87%</strong>. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Staples sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-22.96%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> MGP Ingredients's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-4.75%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> MGP Ingredients's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>-2.92%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> MGP Ingredients's debt-to-equity ratio is below the industry average. With a ratio of <b>0.41</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<p><a href="https://www.benzinga.com/quote/MGPI/earnings"><strong>To track all earnings releases for MGP Ingredients visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


MGPI

Preview: MGP Ingredients's Earnings

<p>Mercer Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MERC#NASDAQ">MERC</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-05-01. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Mercer Intl will report an <strong>earnings per share</strong> (EPS) of $-0.19.</p>
<p>The market awaits Mercer Intl's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Performance in Previous Earnings</h3>
<p>In the previous earnings release, the company beat EPS by $0.20, leading to a 16.87% increase in the share price the following trading session.</p>
<p>Here's a look at Mercer Intl's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.05</td>
<td>0.08</td>
<td>-0.31</td>
<td>-0.11</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.25</td>
<td>-0.26</td>
<td>-1.01</td>
<td>-0.25</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>17.0%</td>
<td>-0.0%</td>
<td>0.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746039748_0.png" alt="eps graph" /></p>
<h3>Mercer Intl Share Price Analysis</h3>
<p>Shares of Mercer Intl were trading at $4.61 as of April 29. Over the last 52-week period, shares are down 86.96%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analysts' Perspectives on Mercer Intl</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Mercer Intl.</p>
<p>The consensus rating for Mercer Intl is Neutral, based on 1 analyst ratings. With an average one-year price target of $6.0, there's a potential 30.15% upside.</p>
<h3>Analyzing Ratings Among Peers</h3>
<p>The analysis below examines the analyst ratings and average 1-year price targets of Clearwater Paper, Magnera and Sylvamo, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Outperform trajectory for Clearwater Paper, with an average 1-year price target of $37.0, suggesting a potential 702.6% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Magnera, with an average 1-year price target of $24.0, suggesting a potential 420.61% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Sylvamo, with an average 1-year price target of $80.0, suggesting a potential 1635.36% upside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
<p>In the peer analysis summary, key metrics for Clearwater Paper, Magnera and Sylvamo are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mercer Intl</td>
<td>Neutral</td>
<td>3.81%</td>
<td>$76.18M</td>
<td>3.53%</td>
</tr>
<tr>
<td>Clearwater Paper</td>
<td>Outperform</td>
<td>44.12%</td>
<td>$14.70M</td>
<td>26.21%</td>
</tr>
<tr>
<td>Magnera</td>
<td>Outperform</td>
<td>119.11%</td>
<td>$71M</td>
<td>-9.14%</td>
</tr>
<tr>
<td>Sylvamo</td>
<td>Neutral</td>
<td>0.62%</td>
<td>$237M</td>
<td>9.08%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Mercer Intl ranks at the bottom for Revenue Growth and Gross Profit among its peers. It is in the middle for Return on Equity.</p>
<h3>Delving into Mercer Intl's Background</h3>
<p>Mercer International Inc is a forest products company with two reportable operating segments in pulp and solid wood. The pulp segment consists of the manufacture, sale, and distribution of pulp, electricity, and chemicals. The company has a geographical presence in the USA, Germany, China, and Other countries, where the majority of revenue is generated from the USA. The majority of the revenue is generated from the Pulp segment.</p>
<h3>A Deep Dive into Mercer Intl's Financials</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Mercer Intl showcased positive performance, achieving a revenue growth rate of <strong>3.81%</strong> as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Materials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Mercer Intl's net margin excels beyond industry benchmarks, reaching <strong>3.42%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Mercer Intl's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>3.53%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Mercer Intl's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>0.7%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>3.47</strong>, Mercer Intl faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<p><a href="https://www.benzinga.com/quote/MERC/earnings"><strong>To track all earnings releases for Mercer Intl visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


MERC

Insights Ahead: Mercer Intl's Quarterly Earnings

<p>RBC Capital  analyst Ben Hendrix   maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Outperform and raises the price target from $183 to $189.</p>


News

Price Target

Analyst Ratings

RBC Capital Maintains Outperform on Tenet Healthcare, Raises Price Target to $189

<p>Kura Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KURA#NASDAQ">KURA</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-05-01. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Kura Oncology will report an <strong>earnings per share</strong> (EPS) of $-0.60.</p>
<p>Anticipation surrounds Kura Oncology's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Earnings History Snapshot</h3>
<p>During the last quarter, the company reported an EPS beat by $0.42, leading to a 1.54% drop in the share price on the subsequent day.</p>
<p>Here's a look at Kura Oncology's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.64</td>
<td>-0.63</td>
<td>-0.63</td>
<td>-0.55</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.22</td>
<td>-0.63</td>
<td>-0.59</td>
<td>-0.59</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-2.0%</td>
<td>-1.0%</td>
<td>-1.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746039736_0.png" alt="eps graph" /></p>
<h3>Market Performance of Kura Oncology's Stock</h3>
<p>Shares of Kura Oncology were trading at $6.52 as of April 29. Over the last 52-week period, shares are down 68.21%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/KURA/earnings"><strong>To track all earnings releases for Kura Oncology visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


KURA

Uncovering Potential: Kura Oncology's Earnings Preview

<p>Mobile learning platform <strong>Duolingo Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) has <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g45093631/duolingo-launches-148-new-language-courses-expands-access-to-popular-languages-including-japanese-" rel="noreferrer noopener">introduced its most extensive </a>course expansion to date, launching 148 new language programs on its platform.</p>
<p>This substantial growth more than doubles its existing offerings. The launch makes Duolingo's top seven non-English languages, Spanish, French, German, Italian, Japanese, Korean, and Mandarin accessible across all 28 of its supported interface languages.</p>
<p>In the past, developing a single language course on Duolingo could take several years. But with the help of generative AI, enhanced internal tools, and a new shared content system, the company has shortened that process, rolling out its newest set of courses in less than a year.</p>
<p><strong>Also Read: <em><a target="_blank" href="https://www.benzinga.com/news/25/04/45040811/marriott-bets-355m-on-trendy-citizenm-hotels-to-woo-modern-travelers" rel="noreferrer noopener">Marriott Bets $355M On Trendy CitizenM Hotels To Woo Modern Travelers</a></em></strong></p>
<p>"Developing our first 100 courses took about 12 years, and now, in about a year, we're able to create and launch nearly 150 new courses. This is a great example of how generative AI can directly benefit our learners," said CEO and co-founder <strong>Luis von Ahn</strong>.</p>
<p>This shared content model enables the creation of a core course structure that can be quickly adapted for multiple languages.</p>
<p>The majority of the newly launched courses are designed for beginners, aligning with A1–A2 levels on the CEFR scale, and include interactive tools such as Stories and DuoRadio to help reading and listening comprehension.</p>
<p>Duolingo noted that higher-level content is expected to be added in the coming months.</p>
<p>The release is especially impactful in regions where access to non-English courses was previously limited. In Latin America, Spanish and Portuguese speakers now have access to Asian languages like Japanese, Mandarin, and Korean.</p>
<p>In Europe, learners speaking languages such as French, German, or Italian can also explore these new additions.</p>
<p>Meanwhile, in Asia, speakers of languages like Hindi, Thai, and Tamil can now learn any of the top seven languages, whereas previously, their options were largely restricted to English.</p>
<p><strong>Price Action</strong>: DUOL shares traded higher by 0.35% at $386.48 at last check Wednesday.</p>
<p><strong>Read Next</strong>:</p>
<ul>
<li><strong><em><a href="https://www.benzinga.com/news/25/04/45011895/the-future-of-flight-united-airlines-invests-in-radical-jet-design" target="_blank" rel="noreferrer noopener">The Future of Flight? United Airlines Invests In Radical Jet Design</a></em></strong></li>
</ul>
<p><em>Photo by DANIEL CONSTANTE via Shutterstock</em></p>


Tech

General

DUOL

Duolingo Launches Its Biggest Expansion Yet With 148 New Courses

<p><strong>Xerox Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRX#NASDAQ">XRX</a>) is set to give its latest quarterly earnings report on Thursday, 2025-05-01. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Xerox Holdings will report an <strong>earnings per share</strong> (EPS) of $0.21. </p>
<p>Anticipation surrounds Xerox Holdings's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Earnings History Snapshot</h3>
<p>Last quarter the company missed EPS by $0.13, which was followed by a 5.79% drop in the share price the next day.</p>
<p>Here's a look at Xerox Holdings's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.49</td>
<td>0.51</td>
<td>0.43</td>
<td>0.35</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.36</td>
<td>0.25</td>
<td>0.29</td>
<td>0.06</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-6.0%</td>
<td>-3.0%</td>
<td>2.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746039719_0.png" alt="eps graph" /></p>
<h3>Market Performance of Xerox Holdings's Stock</h3>
<p>Shares of Xerox Holdings were trading at $4.44 as of April 29. Over the last 52-week period, shares are down 67.18%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/XRX/earnings"><strong>To track all earnings releases for Xerox Holdings visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


What to Expect from Xerox Holdings's Earnings

<p><strong>Illinois Tool Works Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITW#NYSE">ITW</a>) stock was trading lower on Wednesday after the company reported better-than-expected <a href="https://www.benzinga.com/pressreleases/25/04/g45097281/itw-reports-first-quarter-2025-results" target="_blank" rel="noreferrer noopener">first-quarter 2025 results</a>.</p>
<p>The company reported revenue of $3.84 billion, a 3.4% decline year over year, which aligns with the consensus estimate. EPS for the quarter stood at $2.38, down from $2.73 YoY and above the consensus of $2.36.</p>
<p>Organic revenue declined by 1.6%, while organic revenue remained nearly flat on an equal-day basis. Foreign currency translation had a negative impact of 1.8% on revenue.</p>
<p>Revenue By Segments: Automotive OEM $786 million (-3.7% YoY), Food Equipment $627 million (-0.7% YoY), Test &amp; Measurement and Electronics $652 million (-6.3% YoY), Welding $472 million (-0.9% YoY), Polymers &amp; Fluids $429 million (-0.8% YoY), Construction Products $443 million (-9.2% YoY) and Specialty Products $435 million (-1% YoY).</p>
<p>Operating income decreased 15.6% year over year to $951 million, and the operating margin contracted 360 bps to 24.8%. Enterprise initiatives contributed 120 basis points, offset by higher restructuring expenses from 80/20 projects and one-time items.</p>
<p>ITW&#8217;s operating cash flow was $592 million for the quarter, with free cash flow of $496 million, reflecting a 71% conversion to net income. The company repurchased $375 million of its shares during the quarter.</p>
<p>&#8220;Acknowledging the uncertain external environment, we are maintaining our full year 2025 guidance as we expect our ongoing pricing actions to offset tariff cost impacts. ITW is built to outperform in today&#8217;s volatile environment,&#8221; commented <strong>Christopher A. O&#8217;Herlihy</strong>, president and CEO.</p>
<p>&#8220;Our largely &#8216;produce where we sell&#8217; manufacturing strategy, decentralized operating culture which enables rapid &#8216;read and react&#8217; response, and diversified high-quality business portfolio all provide resilience during times of volatility and uncertainty. Our strong financial profile allows us to maintain our strategic investments and focus on driving continued progress on our long-term strategy to make above-market organic growth, fueled by Customer-back Innovation, into a core ITW strength,&#8221; O&#8217;Herlihy concluded.</p>
<p><strong>2025 Guidance reaffirmed:</strong> ITW maintains its GAAP EPS guidance of $10.15 – $10.55 versus the consensus of $10.27.</p>
<p>Revenue and organic growth are projected to be 0-2%, with an operating margin expected between 26.5% and 27.5%.</p>
<p>The free cash flow is expected to exceed 100% of net income, and the company plans to repurchase $1.5 billion in shares. The projected effective tax rate is 24%.</p>
<p><strong>Price Action:</strong> ITW shares traded lower by 3.58% at $233.10 at the last check Wednesday.</p>
<p><em>Photo: Shutterstock</em></p>


Guidance

Illinois Tool Works Faces Q1 Revenue Dip And Lower EPS, Maintains 2025 Guidance Amid Uncertainty

<p>LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) will release its quarterly earnings report on Thursday, 2025-05-01. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate LeMaitre Vascular to report an <strong>earnings per share</strong> (EPS) of $0.50.</p>
<p>The market awaits LeMaitre Vascular's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company missed EPS by $0.00, which was followed by a 8.07% drop in the share price the next day.</p>
<p>Here's a look at LeMaitre Vascular's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.49</td>
<td>0.43</td>
<td>0.47</td>
<td>0.39</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.49</td>
<td>0.49</td>
<td>0.53</td>
<td>0.44</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-8.0%</td>
<td>7.000000000000001%</td>
<td>-1.0%</td>
<td>11.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746039689_0.png" alt="eps graph" /></p>
<h3>Performance of LeMaitre Vascular Shares</h3>
<p>Shares of LeMaitre Vascular were trading at $92.6 as of April 29. Over the last 52-week period, shares are up 34.81%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analysts' Take on LeMaitre Vascular</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on LeMaitre Vascular.</p>
<p>The consensus rating for LeMaitre Vascular is Buy, derived from 3 analyst ratings. An average one-year price target of $105.0 implies a potential 13.39% upside.</p>
<h3>Understanding Analyst Ratings Among Peers</h3>
<p>In this comparison, we explore the analyst ratings and average 1-year price targets of NovoCure, Enovis and QuidelOrtho, three prominent industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for NovoCure, with an average 1-year price target of $29.67, suggesting a potential 67.96% downside.</li>
<li>Analysts currently favor an Buy trajectory for Enovis, with an average 1-year price target of $64.0, suggesting a potential 30.89% downside.</li>
<li>Analysts currently favor an Neutral trajectory for QuidelOrtho, with an average 1-year price target of $43.67, suggesting a potential 52.84% downside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
<p>The peer analysis summary outlines pivotal metrics for NovoCure, Enovis and QuidelOrtho, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>LeMaitre Vascular</td>
<td>Buy</td>
<td>13.98%</td>
<td>$38.59M</td>
<td>3.35%</td>
</tr>
<tr>
<td>NovoCure</td>
<td>Neutral</td>
<td>11.91%</td>
<td>$116.47M</td>
<td>-9.50%</td>
</tr>
<tr>
<td>Enovis</td>
<td>Buy</td>
<td>23.29%</td>
<td>$307.52M</td>
<td>-23.87%</td>
</tr>
<tr>
<td>QuidelOrtho</td>
<td>Neutral</td>
<td>-4.69%</td>
<td>$326.10M</td>
<td>-5.78%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>LeMaitre Vascular ranks highest in Revenue Growth among its peers. It also leads in Gross Profit margin. However, it has the lowest Return on Equity. Overall, LeMaitre Vascular is positioned favorably compared to its peers in terms of financial performance.</p>
<h3>About LeMaitre Vascular</h3>
<p>LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches and vessel closure systems.It has a single operating segment engaged in the development, manufacturing, and marketing of medical devices and implants, as well as the processing and cryopreservation of human tissues for implantation in patients.</p>
<h3>A Deep Dive into LeMaitre Vascular's Financials</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> LeMaitre Vascular's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of <strong>13.98%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> LeMaitre Vascular's net margin is impressive, surpassing industry averages. With a net margin of <strong>20.07%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> LeMaitre Vascular's ROE excels beyond industry benchmarks, reaching <strong>3.35%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> LeMaitre Vascular's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>2.41%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> LeMaitre Vascular's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.55</strong>.</p>
<p><a href="https://www.benzinga.com/quote/LMAT/earnings"><strong>To track all earnings releases for LeMaitre Vascular visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


LMAT

A Look at LeMaitre Vascular's Upcoming Earnings Report

<p><strong>Perdoceo Education</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRDO#NASDAQ">PRDO</a>) is set to give its latest quarterly earnings report on Thursday, 2025-05-01. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Perdoceo Education will report an <strong>earnings per share</strong> (EPS) of $0.66. </p>
<p>Perdoceo Education bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Historical Earnings Performance</h3>
<p>In the previous earnings release, the company beat EPS by $0.02, leading to a 5.9% drop in the share price the following trading session.</p>
<p>Here's a look at Perdoceo Education's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.48</td>
<td>0.53</td>
<td>0.58</td>
<td>0.53</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.50</td>
<td>0.59</td>
<td>0.60</td>
<td>0.60</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-6.0%</td>
<td>12.0%</td>
<td>-1.0%</td>
<td>31.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746039678_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Perdoceo Education were trading at $25.22 as of April 29. Over the last 52-week period, shares are up 4.37%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Insights Shared by Analysts on Perdoceo Education</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Perdoceo Education.</p>
<p>A total of 3 analyst ratings have been received for Perdoceo Education, with the consensus rating being Outperform. The average one-year price target stands at $34.0, suggesting a potential 34.81% upside.</p>
<h3>Peer Ratings Comparison</h3>
<p>The below comparison of the analyst ratings and average 1-year price targets of Afya, Universal Technical and KinderCare Learning, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Sell trajectory for Afya, with an average 1-year price target of $16.0, suggesting a potential 36.56% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Universal Technical, with an average 1-year price target of $34.2, suggesting a potential 35.61% upside.</li>
<li>Analysts currently favor an Buy trajectory for KinderCare Learning, with an average 1-year price target of $24.5, suggesting a potential 2.85% downside.</li>
</ul>
<h3>Overview of Peer Analysis</h3>
<p>The peer analysis summary provides a snapshot of key metrics for Afya, Universal Technical and KinderCare Learning, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Perdoceo Education</td>
<td>Outperform</td>
<td>19.28%</td>
<td>$141.23M</td>
<td>3.32%</td>
</tr>
<tr>
<td>Afya</td>
<td>Sell</td>
<td>0.93%</td>
<td>$517.10M</td>
<td>3.58%</td>
</tr>
<tr>
<td>Universal Technical</td>
<td>Outperform</td>
<td>15.30%</td>
<td>$101.29M</td>
<td>8.20%</td>
</tr>
<tr>
<td>KinderCare Learning</td>
<td>Buy</td>
<td>4.69%</td>
<td>$133.26M</td>
<td>-24.29%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Perdoceo Education ranks first in revenue growth among its peers. It has the lowest gross profit and return on equity.</p>
<h3>About Perdoceo Education</h3>
<p>Perdoceo Education Corp is an American for-profit education company that focuses on quality postsecondary education online to a diverse student population, along with campus-based and blended learning programs. The company's important segments include the American InterContinental University, the University of St. Augustine for Health Sciences, and Colorado Technical University. These universities provide undergraduate, graduate, and doctoral degree programs focusing on business, technology, management, and social services, with the majority of the students enrolled in programs offered fully online. The majority of the company's revenue comes from the Colorado Technical University segment.</p>
<h3>A Deep Dive into Perdoceo Education's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Perdoceo Education's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of <strong>19.28%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Perdoceo Education's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>17.83%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>3.32%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>2.67%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.14</strong>, Perdoceo Education adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<p><a href="https://www.benzinga.com/quote/PRDO/earnings"><strong>To track all earnings releases for Perdoceo Education visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


PRDO

An Overview of Perdoceo Education's Earnings

<p>Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Signet Jewelers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIG#NYSE">SIG</a>) in the last three months.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $67.29, a high estimate of $89.00, and a low estimate of $55.00. A decline of 6.72% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746039672_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The standing of Signet Jewelers among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$60.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$70.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Mauricio Serna</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$89.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$62.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$55.00</td>
<td>$65.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Signet Jewelers. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Signet Jewelers compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Signet Jewelers's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Signet Jewelers's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SIG/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Signet Jewelers analyst ratings.</strong></a></p>
<h2>Discovering Signet Jewelers: A Closer Look</h2>
<p>Signet Jewelers Ltd is a retailer of diamond jewelry. Its merchandise mix includes bridal, fashion, watches, and others. The bridal category includes engagement, wedding and anniversary purchases. Its segments are the North America segment, the International segment, and the Other segment. The North America segment contributes to the majority of the revenue. The North America segment generates revenue from Mall and Off-Mall &amp; Outlet.</p>
<h3>Signet Jewelers: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Signet Jewelers's financials over 3M reveals challenges. As of 31 January, 2025, the company experienced a decline of approximately <strong>-5.81%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Signet Jewelers's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>4.28%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Signet Jewelers's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>5.51%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Signet Jewelers's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>1.76%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Signet Jewelers's debt-to-equity ratio is below the industry average. With a ratio of <b>0.64</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Beyond The Numbers: 7 Analysts Discuss Signet Jewelers Stock

<p>Frontier Group Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULCC#NASDAQ">ULCC</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-05-01. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Frontier Group Holdings will report an <strong>earnings per share</strong> (EPS) of $-0.04.</p>
<p>The announcement from Frontier Group Holdings is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Overview of Past Earnings</h3>
<p>During the last quarter, the company reported an EPS beat by $0.10, leading to a 0.0% drop in the share price on the subsequent day.</p>
<p>Here's a look at Frontier Group Holdings's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.13</td>
<td>-0.03</td>
<td>0.15</td>
<td>-0.18</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.23</td>
<td>-0.05</td>
<td>0.14</td>
<td>-0.09</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>15.0%</td>
<td>0.0%</td>
<td>-2.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746039667_0.png" alt="eps graph" /></p>
<h3>Frontier Group Holdings Share Price Analysis</h3>
<p>Shares of Frontier Group Holdings were trading at $3.13 as of April 29. Over the last 52-week period, shares are down 49.24%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<h3>Analyst Observations about Frontier Group Holdings</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Frontier Group Holdings.</p>
<p>Analysts have provided Frontier Group Holdings with 11 ratings, resulting in a consensus rating of Neutral. The average one-year price target stands at $7.02, suggesting a potential 124.28% upside.</p>
<h3>Analyzing Analyst Ratings Among Peers</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of Allegiant Travel, Sun Country Airlines and Blade Air Mobility, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Allegiant Travel, with an average 1-year price target of $64.43, suggesting a potential 1958.47% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Sun Country Airlines, with an average 1-year price target of $14.5, suggesting a potential 363.26% upside.</li>
<li>Analysts currently favor an Buy trajectory for Blade Air Mobility, with an average 1-year price target of $6.5, suggesting a potential 107.67% upside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
<p>Within the peer analysis summary, vital metrics for Allegiant Travel, Sun Country Airlines and Blade Air Mobility are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Frontier Group Holdings</td>
<td>Neutral</td>
<td>12.46%</td>
<td>$83M</td>
<td>9.19%</td>
</tr>
<tr>
<td>Allegiant Travel</td>
<td>Neutral</td>
<td>2.73%</td>
<td>$115.95M</td>
<td>-18.10%</td>
</tr>
<tr>
<td>Sun Country Airlines</td>
<td>Neutral</td>
<td>6.05%</td>
<td>$58.63M</td>
<td>2.39%</td>
</tr>
<tr>
<td>Blade Air Mobility</td>
<td>Buy</td>
<td>14.49%</td>
<td>$12.59M</td>
<td>-4.30%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Frontier Group Holdings ranks in the middle for revenue growth among its peers. It ranks at the bottom for gross profit. It ranks at the top for return on equity.</p>
<h3>Delving into Frontier Group Holdings's Background</h3>
<p>Frontier Group Holdings Inc is an ultra-low-cost carrier whose business is focused on Low Fares Done Right. The company owns a fleet of 120 Airbus single-aisle aircraft, consisting of 13 A320ceos, 82 A320neos, 21 A321ceos and 4 A321neos. The use of these aircraft, their seating configuration, weight-saving tactics, and baggage process have all contributed to the ability to continue to be the fuel-efficient of all the U.S. The Company is managed as a single business unit that provides air transportation for passengers. Majority of revenue is from Domestic flight follow by International.</p>
<h3>Frontier Group Holdings: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Frontier Group Holdings's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of <strong>12.46%</strong>. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> Frontier Group Holdings's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>5.29%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Frontier Group Holdings's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>9.19%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Frontier Group Holdings's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>0.88%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Frontier Group Holdings's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>7.4</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<p><a href="https://www.benzinga.com/quote/ULCC/earnings"><strong>To track all earnings releases for Frontier Group Holdings visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


ULCC

Insights into Frontier Group Holdings's Upcoming Earnings

<p>4 analysts have expressed a variety of opinions on Equity Residential (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQR#NYSE">EQR</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Equity Residential and provided 12-month price targets. The average target is $78.25, accompanied by a high estimate of $80.00 and a low estimate of $76.00. Surpassing the previous average price target of $77.56, the current average has increased by 0.89%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746039665_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The standing of Equity Residential among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Simon Yarmak</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$80.00</td>
<td>$82.25</td>
</tr>
<tr>
<td>Michael Lewis</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$78.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$79.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$76.00</td>
<td>$74.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Equity Residential. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Equity Residential compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Equity Residential's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Equity Residential's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/EQR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Equity Residential analyst ratings.</strong></a></p>
<h2>Delving into Equity Residential's Background</h2>
<p>Equity Residential owns a portfolio of 311 apartment communities with around 84,000 units and is developing two additional properties with 655 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.</p>
<h3>Equity Residential: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Equity Residential's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>5.4%</strong> as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Real Estate sector.</p>
<p><strong>Net Margin:</strong> Equity Residential's net margin excels beyond industry benchmarks, reaching <strong>54.61%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Equity Residential's ROE excels beyond industry benchmarks, reaching <strong>3.83%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Equity Residential's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>2.01%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.76</strong>.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Assessing Equity Residential: Insights From 4 Financial Analysts

<p><strong>Cohu</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COHU#NASDAQ">COHU</a>) is set to give its latest quarterly earnings report on Thursday, 2025-05-01. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Cohu will report an <strong>earnings per share</strong> (EPS) of $-0.17. </p>
<p>Anticipation surrounds Cohu's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company missed EPS by $0.06, which was followed by a 1.63% drop in the share price the next day.</p>
<p>Here's a look at Cohu's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.09</td>
<td>-0.07</td>
<td>-0.02</td>
<td>-0.01</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.15</td>
<td>-0.08</td>
<td>-0.01</td>
<td>0.01</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-2.0%</td>
<td>10.0%</td>
<td>-12.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746039659_0.png" alt="eps graph" /></p>
<h3>Cohu Share Price Analysis</h3>
<p>Shares of Cohu were trading at $16.5 as of April 29. Over the last 52-week period, shares are down 47.92%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/COHU/earnings"><strong>To track all earnings releases for Cohu visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


COHU

Cohu's Earnings: A Preview

<p>In the latest quarter, 11 analysts provided ratings for Honeywell Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Honeywell Intl, revealing an average target of $230.18, a high estimate of $260.00, and a low estimate of $178.00. Experiencing a 1.52% decline, the current average is now lower than the previous average price target of $233.73. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746039653_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Honeywell Intl. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph O'Dea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$225.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$226.00</td>
<td>$211.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$243.00</td>
<td>$247.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$229.00</td>
<td>$253.00</td>
</tr>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$178.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$247.00</td>
<td>$251.00</td>
</tr>
<tr>
<td>Chris Snyder</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$217.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$251.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$236.00</td>
<td>$253.00</td>
</tr>
<tr>
<td>Joseph O'Dea</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$220.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Nicole Deblase</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$260.00</td>
<td>$236.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Honeywell Intl. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Honeywell Intl compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Honeywell Intl's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Honeywell Intl's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/HON/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Honeywell Intl analyst ratings.</strong></a></p>
<h2>About Honeywell Intl</h2>
<p>Honeywell traces its roots to 1885 with Albert Butz's firm, Butz Thermo-Electric Regulator, which produced a predecessor to the modern thermostat. Other inventions by Honeywell include biodegradable detergent and autopilot. Today, Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. It operates through four business segments: aerospace technologies (37% of 2023 company revenue), industrial automation (29%), energy and sustainability solutions (17%), and building automation (17%). Recently, Honeywell has made several portfolio changes to focus on fewer end markets and align with a set of secular growth trends. The firm is working diligently to expand its installed base, deriving around 30% of its revenue from recurring aftermarket services.</p>
<h3>Unraveling the Financial Story of Honeywell Intl</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Revenue Growth:</strong> Over the 3M period, Honeywell Intl showcased positive performance, achieving a revenue growth rate of <strong>6.86%</strong> as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> Honeywell Intl's net margin is impressive, surpassing industry averages. With a net margin of <strong>12.74%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Honeywell Intl's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>7.13%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Honeywell Intl's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>1.73%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Honeywell Intl's debt-to-equity ratio is below the industry average at <strong>1.73</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Deep Dive Into Honeywell Intl Stock: Analyst Perspectives (11 Ratings)

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Morgan Stanley</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MS, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 10 uncommon options trades for Morgan Stanley.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 30% bullish and 70%, bearish.</p>
<p>Out of all of the special options we uncovered, 6 are puts, for a total amount of $184,271, and 4 are calls, for a total amount of $125,960.</p>
<h3>Predicted Price Range</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $50.0 to $120.0 for Morgan Stanley over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Morgan Stanley's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Morgan Stanley's whale trades within a strike price range from $50.0 to $120.0 in the last 30 days. </p>
<h3>Morgan Stanley 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746039650_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$7.3</td>
<td>$7.2</td>
<td>$7.27</td>
<td>$115.00</td>
<td>$34.1K</td>
<td>3.1K</td>
<td align="right">12</td>
</tr>
<tr>
<td>MS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$64.95</td>
<td>$64.3</td>
<td>$64.78</td>
<td>$50.00</td>
<td>$32.3K</td>
<td>57</td>
<td align="right">18</td>
</tr>
<tr>
<td>MS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$65.35</td>
<td>$64.45</td>
<td>$64.77</td>
<td>$50.00</td>
<td>$32.3K</td>
<td>57</td>
<td align="right">8</td>
</tr>
<tr>
<td>MS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$64.85</td>
<td>$64.15</td>
<td>$64.66</td>
<td>$50.00</td>
<td>$32.3K</td>
<td>57</td>
<td align="right">13</td>
</tr>
<tr>
<td>MS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$1.93</td>
<td>$1.92</td>
<td>$1.93</td>
<td>$100.00</td>
<td>$31.6K</td>
<td>12.6K</td>
<td align="right">168</td>
</tr>
</tbody>
</table>
</p>
<h3>About Morgan Stanley</h3>
<p>Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments with approximately 45% of net revenue from its institutional securities business, 45% from wealth management, and 10% from investment management. About 24% of its total revenue is from outside the Americas. The company had over $6 trillion of client assets as well as around 70,000 employees at the end of 2024.</p>
<p>In light of the recent options history for Morgan Stanley, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Present Market Standing of Morgan Stanley</h3>
<ul>
<li>With a trading volume of 3,303,083, the price of MS is down by -1.12%, reaching $114.0.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 77 days from now.</li>
</ul>
<h3>Expert Opinions on Morgan Stanley</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $129.8.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Neutral rating for Morgan Stanley, targeting a price of $125.<br />
&#x2A; An analyst from Wells Fargo persists with their Equal-Weight rating on Morgan Stanley, maintaining a target price of $120.<br />
&#x2A; An analyst from JP Morgan persists with their Neutral rating on Morgan Stanley, maintaining a target price of $122.<br />
&#x2A; An analyst from B of A Securities persists with their Buy rating on Morgan Stanley, maintaining a target price of $144.<br />
&#x2A; An analyst from Evercore ISI Group has decided to maintain their Outperform rating on Morgan Stanley, which currently sits at a price target of $138. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Morgan Stanley with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


Options

Markets

What the Options Market Tells Us About Morgan Stanley

<p>Financial giants have made a conspicuous bearish move on Amgen. Our analysis of options history for Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) revealed 8 unusual trades.</p>
<p>Delving into the details, we found 12% of traders were bullish, while 37% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $128,590, and 4 were calls, valued at $1,226,500.</p>
<h3>What's The Price Target?</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $190.0 to $300.0 for Amgen during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Amgen's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Amgen's substantial trades, within a strike price spectrum from $190.0 to $300.0 over the preceding 30 days.</p>
<h3>Amgen 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746039645_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$22.3</td>
<td>$20.6</td>
<td>$21.3</td>
<td>$280.00</td>
<td>$958.5K</td>
<td align="right">208</td>
<td align="right">450</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/02/25</td>
<td>$19.8</td>
<td>$19.5</td>
<td>$19.5</td>
<td>$270.00</td>
<td>$117.0K</td>
<td align="right">46</td>
<td align="right">80</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$101.8</td>
<td>$98.2</td>
<td>$100.0</td>
<td>$190.00</td>
<td>$100.0K</td>
<td align="right">11</td>
<td align="right">10</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/02/25</td>
<td>$5.1</td>
<td>$4.8</td>
<td>$5.1</td>
<td>$292.50</td>
<td>$50.9K</td>
<td align="right">243</td>
<td align="right">177</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/18/26</td>
<td>$36.0</td>
<td>$35.85</td>
<td>$35.9</td>
<td>$290.00</td>
<td>$35.9K</td>
<td align="right">77</td>
<td align="right">10</td>
</tr>
</tbody>
</table>
</p>
<h3>About Amgen</h3>
<p>Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.</p>
<p>After a thorough review of the options trading surrounding Amgen, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Amgen's Current Market Status</h3>
<ul>
<li>Trading volume stands at 1,025,524, with AMGN's price up by 0.12%, positioned at $288.92.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 1 days.</li>
</ul>
<h3>What Analysts Are Saying About Amgen</h3>
<p>Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $324.5.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Neutral rating for Amgen, targeting a price of $319.<br />
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Equal-Weight rating for Amgen, targeting a price of $330. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Amgen with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


AMGN

Looking At Amgen's Recent Unusual Options Activity

<p>In the last three months, 24 analysts have published ratings on Snap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">20</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">9</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Snap, presenting an average target of $10.27, a high estimate of $14.50, and a low estimate of $8.00. Highlighting a 18.36% decrease, the current average has fallen from the previous average price target of $12.58. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746039644_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>A clear picture of Snap's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Naved Khan</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$10.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Youssef Squali</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$11.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$8.50</td>
<td>$9.50</td>
</tr>
<tr>
<td>Shyam Patil</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$8.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$8.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Brian Pitz</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$13.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Barton Crockett</td>
<td>Rosenblatt</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$9.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Mark Kelley</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$8.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Brian Nowak</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$8.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Maria Ripps</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$10.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Ronald Josey</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$9.00</td>
<td>$13.50</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$9.50</td>
<td>$13.50</td>
</tr>
<tr>
<td>Lloyd Walmsley</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$9.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Thomas Champion</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$10.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Justin Post</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$10.50</td>
<td>$14.50</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$8.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$9.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Devin Ryan</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$14.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Shyam Patil</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Neutral</td>
<td>$13.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$10.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Ronald Josey</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$13.50</td>
<td>$13.00</td>
</tr>
<tr>
<td>Justin Post</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$14.50</td>
<td>$14.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$11.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Snap. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Snap compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Snap's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Snap's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SNAP/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Snap analyst ratings.</strong></a></p>
<h2>Get to Know Snap Better</h2>
<p>Snap is a technology company best known for its marquis social media application Snapchat, a visual messaging application that has amassed hundreds of millions of users. The app was initially only used to communicate with family and friends through photographs and short videos (known as "Snaps"). Users can now enjoy augmented reality, or AR, lenses, content from famous creators and celebrities, updates about local events, and more. Although the app offers a paid subscription option with premium features, advertising sales produce most of the app's revenue. The firm also sells wearable devices called AR Spectacles, which can capture photos and videos overlayed with AR lenses, but these make up a small portion of Snap's overall sales.</p>
<h3>Snap: Delving into Financials</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Snap's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of <strong>14.4%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Communication Services sector.</p>
<p><strong>Net Margin:</strong> Snap's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>0.58%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Snap's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>0.39%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Snap's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>0.12%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Snap's debt-to-equity ratio surpasses industry norms, standing at <strong>1.73</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


SNAP

What Analysts Are Saying About Snap Stock

<p>Financial giants have made a conspicuous bullish move on Procter &amp; Gamble. Our analysis of options history for Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) revealed 10 unusual trades.</p>
<p>Delving into the details, we found 50% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $138,870, and 7 were calls, valued at $267,805.</p>
<h3>Predicted Price Range</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $130.0 to $165.0 for Procter &amp; Gamble during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Procter &amp; Gamble's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Procter &amp; Gamble's whale trades within a strike price range from $130.0 to $165.0 in the last 30 days. </p>
<h3>Procter &amp; Gamble 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746039640_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>PG</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$9.1</td>
<td>$9.0</td>
<td>$9.1</td>
<td>$165.00</td>
<td>$81.9K</td>
<td>2.0K</td>
<td align="right">104</td>
</tr>
<tr>
<td>PG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$7.65</td>
<td>$7.45</td>
<td>$7.65</td>
<td>$165.00</td>
<td>$48.1K</td>
<td>1.2K</td>
<td align="right">70</td>
</tr>
<tr>
<td>PG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$4.4</td>
<td>$4.2</td>
<td>$4.27</td>
<td>$160.00</td>
<td>$42.6K</td>
<td>587</td>
<td align="right">335</td>
</tr>
<tr>
<td>PG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$20.05</td>
<td>$19.65</td>
<td>$20.0</td>
<td>$150.00</td>
<td>$40.0K</td>
<td>371</td>
<td align="right">20</td>
</tr>
<tr>
<td>PG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/02/25</td>
<td>$0.94</td>
<td>$0.92</td>
<td>$0.93</td>
<td>$162.50</td>
<td>$38.2K</td>
<td>680</td>
<td align="right">573</td>
</tr>
</tbody>
</table>
</p>
<h3>About Procter &amp; Gamble</h3>
<p>Since its founding in 1837, Procter &amp; Gamble has become one of the world's largest consumer product manufacturers, with annual sales approaching $85 billion. It operates with a lineup of leading brands, including more than 20 that generate north of $1 billion each in annual global sales, such as Tide laundry detergent, Charmin toilet paper, Pantene shampoo, and Pampers diapers. Sales outside its home turf represent just more than half of the firm's consolidated total.</p>
<p>Following our analysis of the options activities associated with Procter &amp; Gamble, we pivot to a closer look at the company's own performance.</p>
<h3>Current Position of Procter &amp; Gamble</h3>
<ul>
<li>With a trading volume of 3,779,792, the price of PG is down by -0.44%, reaching $161.54.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 90 days from now.</li>
</ul>
<h3>Expert Opinions on Procter &amp; Gamble</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $177.2.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Truist Securities keeps a Buy rating on Procter &amp; Gamble with a target price of $180.<br />
&#x2A; An analyst from Truist Securities persists with their Buy rating on Procter &amp; Gamble, maintaining a target price of $185.<br />
&#x2A; An analyst from RBC Capital upgraded its action to Outperform with a price target of $177.<br />
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Overweight rating on Procter &amp; Gamble with a target price of $180.<br />
&#x2A; An analyst from RBC Capital has revised its rating downward to Sector Perform, adjusting the price target to $164. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Procter &amp; Gamble, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Procter & Gamble's Options Frenzy: What You Need to Know

<p>ThredUp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDUP#NASDAQ">TDUP</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated ThredUp and provided 12-month price targets. The average target is $4.5, accompanied by a high estimate of $6.00 and a low estimate of $3.00. This upward trend is evident, with the current average reflecting a 50.0% increase from the previous average price target of $3.00.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746039635_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The perception of ThredUp by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$6.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$6.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$3.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$3.00</td>
<td>$3.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to ThredUp. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of ThredUp compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of ThredUp's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TDUP/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on ThredUp analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About ThredUp</h2>
<p>ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app and RaaS partners. Geographically, the majority of the company's revenue is generated from United States.</p>
<h3>ThredUp: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Positive Revenue Trend:</strong> Examining ThredUp's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>54.78%</strong> as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>-78.46%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> ThredUp's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-34.57%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> ThredUp's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-11.24%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>1.05</strong>.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


TDUP

A Glimpse Into The Expert Outlook On ThredUp Through 4 Analysts

Press Releases

KKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

Cactus Announces Timing of Second Quarter 2024 Earnings Release and Conference Call

Cactus Announces Second Quarter 2024 Results

Cactus Announces Timing of Third Quarter 2024 Earnings Release and Conference Call

Cactus Announces Third Quarter 2024 Results

Teekay Group Announces Changes to Boards of Directors

Cactus Announces Quarterly Cash Dividend

Cactus Announces Timing of Fourth Quarter and Full Year 2024 Earnings Release and Conference Call

Cactus Announces Fourth Quarter and Full Year 2024 Results

Cactus Announces Timing of First Quarter 2025 Earnings Release and Conference Call

ADTN

ALTR

ATNI

BMRN

CLDT

CODI

CRNC

CRWD

GDDY

HOUS

IART

ILMN

KRYS

NFBK

OSUR

PENN

SPGI

STEP

TTEC

VIRT

WERN

XPER

ProFrac Holding Corp. - Class A Common Stock

ProFrac Holding

Atlas Energy Solutions

Aris Water Solutions, Inc. Class A Common Stock

Aris Water Solutions

Archrock

Baker Hughes

ChampionX

Flowco Holdings Inc. Class A Common Stock

Flowco Holdings

TechnipFMC

Halliburton

Helix Energy Solutions Group, Inc. Common Stock

Helix Energy Solns Gr

Innovex International

Kodiak Gas Services

Liberty Energy

National Energy Services Reunited Corp - Ordinary Shares

National Energy Services

Oceaneering International, Inc. Common Stock

Oceaneering International

Solaris Energy Infrastructure, Inc. Class A Common Stock

Solaris Energy

Schlumberger

Tidewater

Tenaris

USA Compression Partners, LP Common Units Representing Limited Partner Interests

Comments

Cactus

空売り

Cactus (NYSE:WHD) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル